Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAGE Therapeutics (SAGE)
NASDAQ:SAGE
SAGE Therapeutics (SAGE) Stock Price & Analysis
846 Followers
SAGE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$15.06 - $59.99
Previous Close$15.32
Volume1.31M
Average Volume (3M)901.98K
Market Cap
$929.25M
Enterprise Value$51.75M
Total Cash (Recent Filing)$876.05M
Total Debt (Recent Filing)$6.97M
Price to Earnings (P/E)-1.7
Beta0.95
Next Earnings
Apr 25, 2024EPS Estimate
-$1.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-9.05
Shares Outstanding60,106,687
10 Day Avg. Volume803,008
30 Day Avg. Volume901,976
Standard Deviation0.16
R-Squared0.08
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.14
Price to Sales (P/S)119.81
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.57
Enterprise Value/Gross Profit6.73
Enterprise Value/Ebitda-0.08
Forecast
1Y Price Target
$25.50Price Target Upside64.94% Upside
Rating ConsensusHold
Number of Analyst Covering15
SAGE Therapeutics News
PremiumCompany Announcements
SAGE Therapeutics’ Promising Parkinson’s Treatment Results
PremiumCompany Announcements
SAGE Therapeutics Board Member Announces Retirement
Ownership Overview
7.92% Insiders
35.58% Mutual Funds
19.83% Other Institutional Investors
36.68% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAGE FAQ
What was SAGE Therapeutics’s price range in the past 12 months?
SAGE Therapeutics lowest stock price was $15.06 and its highest was $59.99 in the past 12 months.
What is SAGE Therapeutics’s market cap?
Currently, no data Available
When is SAGE Therapeutics’s upcoming earnings report date?
SAGE Therapeutics’s upcoming earnings report date is Apr 25, 2024 which is in 8 days.
How were SAGE Therapeutics’s earnings last quarter?
SAGE Therapeutics released its earnings results on Feb 14, 2024. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$1.277 by $0.727.
Is SAGE Therapeutics overvalued?
According to Wall Street analysts SAGE Therapeutics’s price is currently Undervalued.
Does SAGE Therapeutics pay dividends?
SAGE Therapeutics does not currently pay dividends.
What is SAGE Therapeutics’s EPS estimate?
SAGE Therapeutics’s EPS estimate is -$1.61.
How many shares outstanding does SAGE Therapeutics have?
SAGE Therapeutics has 60,106,686 shares outstanding.
What happened to SAGE Therapeutics’s price movement after its last earnings report?
SAGE Therapeutics reported an EPS of -$0.55 in its last earnings report, beating expectations of -$1.277. Following the earnings report the stock price went up 11.859%.
Which hedge fund is a major shareholder of SAGE Therapeutics?
Among the largest hedge funds holding SAGE Therapeutics’s share is Fisher Asset Management LLC. It holds SAGE Therapeutics’s shares valued at 9M.
---
SAGE Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$25.50 (64.94% Upside)
$25.50 (64.94% Upside)
Blogger Sentiment
Bullish
SAGE Sentiment 66%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 63.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.15%
12-Months-Change
Fundamentals
Return on Equity
-52.77%
Trailing 12-Months
Asset Growth
-34.96%
Trailing 12-Months
Company Description
SAGE Therapeutics
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
---
SAGE Company Deck
---
SAGE Earnings Call
Q4 2024
0:00 / 0:00
---
SAGE Stock 12 Months Forecast
Average Price Target
$25.50
▲(64.94% Upside)
Technical Analysis
Best Analysts Covering SAGE
1 Year
1 Year Success Rate
8/27 ratings generated profit
1 Year Average Return
-18.73%
reiterated a buy rating 2 months ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 29.63% of your transactions generating a profit, with an average return of -18.73% per trade.
---